Jasper Therapeutics, Inc. Logo

Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | NDAQ

Overview

Corporate Details

ISIN(s):
US4718712023 (+3 more)
LEI:
Country:
United States of America
Address:
2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America CUPR
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curanex Pharmaceuticals Inc Logo
Developing botanical drugs for inflammatory diseases, diabetes, and COVID-19.
United States of America CURX
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC

Talk to a Data Expert

Have a question? We'll get back to you promptly.